Please assess the completion status of the following clinical trial:

Trial Title: Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Negative pregnancy test for women of childbearing potential within 3 days prior to baseline evaluation and use of an acceptable means of contraception (condom, hormonal or mechanical method) for one month prior to immunization and for all the duration of the study;~* Complete blood count and differential defined as:~* Hematocrit \>=30% for women, \>= 38% for men~* Hemoglobin \>= 9.5 g/dL~* White cell counts \>= 4,000 and \<= 9,500 cells/mm3~* Total lymphocyte count \>=1000 cells/mm3~* CD4+ T cell count \> 500 cells/microL based on 2 separate determinations (Hannet, 1992)~* Platelets (100,000-550,000/ mm3)~* Differential within institutional normal limits or approval of site physician;~* Normal ALT (as defined by the range of the clinical site laboratory) and Creatinine (\< 1.6 mg/dl);~* Normal urine dipstick with esterase and nitrite;~* Normal thyroid function;~* Negative ELISA for HIV-1/HIV-2 and HIV-1 viral load (plasma viremia) \< 50 copies/mL within 1 month of immunization;~* Availability for follow-up for planned duration of at least 12 months and willing to have further brief evaluations at 24 and 36 months;~* Signed informed consent.~Exclusion Criteria:~* Identifiable high-risk behavior for HIV-1 infection, including a history of injection drug use within 12 months prior to enrollment or higher-risk sexual behavior;~* History of neoplastic diseases, encephalopathy, neuropathy or unstable CNS pathology, immunodeficiency, autoimmune disease, angina or cardiac arrhythmias, or any other clinically significant medical problems;~* Chest radiography showing evidence of active or acute cardiac or pulmonary disease;~* History of anaphylaxis or serious adverse reactions to vaccines as well as serum IgE levels exceeding 1000 U.I./ml;~* History of serious allergic reaction to any substance, requiring hospitalization or emergent medical care (e.g. Steven-Johnson syndrome, bronchospasm, or hypotension);~* Active syphilis \[NOTE. If the serology is documented to be a false positive or due to an adequately treated infection, the volunteer is eligible\];~* Active tuberculosis \[NOTE: Volunteers with a positive PPD and a normal chest X-ray showing no evidence of TB and not requiring isoniazid (INH) therapy are eligible\];~* Medical or psychiatric condition or occupational responsibilities which preclude subject compliance with the protocol. Specifically excluded are persons with psychotic disorders, major affective disorders, suicidal ideation;~* Current use of psychotropic drugs;~* Participation in another experimental protocol within six months prior to pre-study screening;~* Current or prior therapy with immunomodulators or immunosuppressive drugs and anticoagulant drugs within 30 days prior to study medication administration;~* Any unstable cardiovascular disease (e.g. unstable hypersensitive disease needing modification or introduction of an anti-hypersensitive treatment);~* Live attenuated vaccines within 60 days of study \[NOTE: Medically indicated sub-unit or killed vaccines (e.g., influenza, pneumococcal, hepatitis A and B) are not exclusionary, but should be given at least 4 weeks away from HIV immunizations\];~* Use of investigational agents within 90 days prior to study;~* Receipt of blood products or immunoglobulin in the past 6 months;~* Prior receipt of HIV-1 vaccine in a previous HIV vaccine trial;~* Positivity for HBV antigens (HBs Ag, HBe Ag), and HCV, HTLV-I and HTLV-II antibodies;~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: OTHER): Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
- B (Type: OTHER): Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), or with Saline, as placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete